Cosmos Health Signs an Agreement with Virax Biolabs to Distribute Monkeypox Virus Real-Time PCR Detections Kits in Europe
Cosmos Holdings (NASDAQ: COSM) has signed an exclusive agreement with Virax Biolabs to distribute Monkeypox Virus Real-Time PCR Detection Kits in Greece and Cyprus, with potential for broader distribution in Europe. The deal aims to meet the increasing demand for efficient Monkeypox testing, as highlighted by the CDC's report of over 61,282 confirmed cases globally. CEO Greg Siokas expressed optimism about the partnership enhancing market access for these crucial diagnostic tools.
- Exclusive distribution rights for Monkeypox testing kits in Greece and Cyprus.
- Opportunity for non-exclusive distribution across Europe.
- Market demand for fast testing methods for Monkeypox virus.
- None.
CHICAGO, IL / ACCESSWIRE / September 22, 2022 / Cosmos Holdings d/b/a Cosmos Health, Inc. ("Cosmos") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits. Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis.
"We are enthusiastic about the combination of Virax Biolabs' strong distribution and Cosmos' considerable knowledge of the market, in order to make these important and convenient testing tools a success" stated Greg Siokas, Chief Executive Officer of Cosmos Health. "Based on our conversations with our customers, we see a demand for fast and conducive testing methods for Monkeypox Virus. We view this agreement as a first step in a longstanding relationship with Virax"
Virax Biolabs, founded in 2013, is a UK based diagnostics company focused on the prevention, detection and diagnosis of viral diseases, with a particular interest in the field of immunology. The test is intended to aid in the rapid diagnosis of Monkeypox virus in human serum and lesion exudate specimens, providing a preliminary test result. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status.
Virax's Chairman of the Board of Directors and Chief Executive Officer, Mr. James Foster, commented, "These real-time PCR Monkeypox tests facilitate the rapid diagnosis, treatment and containment of a very significant viral infection, so we are very excited to work with Cosmos to help provide access to it in Europe. We are working diligently to sign additional regional partnerships across the globe as approximately 104 countries have reported cases of Monkeypox."
According to the US Centers for Disease Control (CDC), 61,282 laboratory confirmed cases of Monkeypox have been reported in 104 countries as of September 16, 20221 with 97 of these nations having never reported cases of monkeypox previously. Monkeypox was declared as a global health emergency by the World Health Organization and is caused by an orthopoxvirus and can be transmitted from animals to humans or human to human. Symptoms can begin with a high fever, headaches, body aches, and fatigue. After about two days, blistering rashes and boils on the face, hands, and feet start. Patients are advised to be in isolation throughout the duration of the disease, which can last approximately three to four weeks.
About Cosmos Health, Inc.
Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Lytham Partners, LLC
Ben Shamsian
E: shamsian@lythampartners.com
P: 646-829-9701
SOURCE: Cosmos Holdings, Inc.
View source version on accesswire.com:
https://www.accesswire.com/717037/Cosmos-Health-Signs-an-Agreement-with-Virax-Biolabs-to-Distribute-Monkeypox-Virus-Real-Time-PCR-Detections-Kits-in-Europe
FAQ
What is the recent agreement signed by Cosmos Holdings?
What are the distribution rights for the Monkeypox testing kits?
How does the CDC report impact Cosmos Holdings?
What is the significance of the partnership with Virax Biolabs?
What is the stock symbol for Cosmos Holdings?
